Advancements in natural and modern treatments for Alzheimer's disease in preclinical and early stages

Background: Alzheimer's disease (AD), the most common cause of dementia, is characterized by memory loss, cognitive decline, and behavioral changes. Current monoclonal antibodies raise concerns about cost and safety, despite modest disease-modifying effects. Methodology: Evidence from preclinical research, clinical trials, and meta-analyses on integrative methods for managing AD is compiled in this narrative review. We assessed natural phytochemicals (from plants like Ginkgo biloba, Bacopa monnieri, Withania somnifera, Curcuma longa, and Salvia officinalis), lifestyle modifications, and new technologies. With an emphasis on preclinical and early-stage AD data through 2025, standardized extracts such as EGb761 and saffron were given priority. Results: Certain plants' phytochemicals have anti-inflammatory, anti-amyloid, antioxidant, and neurotrophic properties that alter important AD pathways. Standardized extracts such as EGb761 and saffron have been shown in clinical trials to provide cognitive benefits comparable to those of prescription medications, with fewer side effects. Pharmacotherapy, natural modulators, stem cell therapy, AI-driven precision medicine, and other integrative strategies have shown promise in slowing disease progression. Discussion: Low bioavailability, formulation variability, and a lack of large-scale trials are some of the issues facing clinical translation. Natural remedies can complement modern treatments, particularly during the early stages of AD. Standardized formulations, sophisticated delivery methods, and thorough verification of synergistic strategies are essential for future success. Conclusion: Modern and natural therapies present promising options for managing AD at an early stage. Integrative care must be advanced through standardized formulations, enhanced delivery techniques, and robust clinical validation of synergistic approaches.